



MicroRNA and Cancer Immunology

Guest Editor:

Dr. Behzad Mansoori

Cellular and Molecular
Oncogenesis Program, The
Wistar Institute, Philadelphia, PA
19104, USA

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editor

Dear Colleagues,

I am pleased to invite you to contribute to this Special Issue on "MicroRNA and Cancer Immunology" in *Cancers*. This issue seeks to illuminate the critical role of microRNAs (miRNAs) in the complex interplay within the tumor microenvironment and their impact on cancer progression. Recent research underscores the significance of miRNAs as modulators of immune cell function, tumor angiogenesis, and epithelial–mesenchymal transition (EMT). Their potential as biomarkers and therapeutic targets in cancer diagnosis, prognosis, and treatment highlights the importance of this burgeoning field.

This Special Issue aims to collate and disseminate cutting-edge research and reviews exploring the multifaceted roles of miRNAs in cancer immunology. Our goal is to provide a comprehensive overview of current advances and encourage discussions that may shape future research directions in this vital area.

In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions and fostering a rich dialogue in this dynamic and vital field of cancer research.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)